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ABSTRACT
The fluorinated hydrocarbons that are used for anesthesia are derived from ether. Al-
though they have many benefits, there are several side effects of these drugs, includ-
ing untoward hepatic effects. Whether the use of halothane gas can be revitalized is 
unknown. Introducing nanocarriers inside the halothane molecule can increase its 
benefits as an anesthetic in the lungs and cardiovascular system and prevent exposure 
to the liver. The findings of new fields, such as cancer therapy, and anesthetic agents, 
such as propofol, can improve the quality of the drug using nanomedicine.
ARTICLE INFO
Article history:
Received: 03 Apr 2011
Revised: 04 Apr 2011
Accepted: 07 Apr 2011
Keywords:
Halothane
Nanotechnology
Anesthesiology
Hepatitis
Article Type:
Editorial
  c 2011 Kowsar M.P.Co. All rights reserved.
  Implication for health policy/practice/research/medical education:
Halothane is an inhalational anesthetic agent with multiple benefits, but an important untoward effect. There is a chance for produc-
ing this drug with the newly proposed nanotechnology. Regarding its financial benefits, it is commonly used until producing the 
new generation of any other anesthetic drug..
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1. Introduction
The  fluorinated  hydrocarbons  that  are  used  for 
anesthesia  are  derived  from  ether.  Despite  their 
benefit,  there  are  several  side  effects  of  these  drugs. 
One  of  these  agents  halothane,  a  true  innovation  in 
the  pharmacology  of  anesthesia,  was  introduced  in 
the 1950s by Charles Suckling, a British chemist, over 2 
years  of  research  and  retesting  (1-3).  James  Raventon 
evaluated  the  pharmacological  characteristics  of  the 
drug, and finally, Michael Johnston, a famous physician 
and anesthesiologist, described its clinical superiorities. 
Not  too  many  years  were  needed  to  recognize  the 
first clinical presentation of a side effect, later termed 
halothane-induced hepatitis, in a 39-year-old woman in 
1958 (3-5). This occurrence became a major trigger for the 
production of less harmful anesthetic gases (5).
There are 2 types of this reaction to halothane involving 
the  liver:  type  1,  or  mild  hepatitis,  is  accompanied  by 
increased levels of plasma transaminases and is a self-
limited  process  (6,  7);  type  2  is  severe  hepatotoxicity 
(6-8), associated with acute hepatic failure and mortality. 
The  most  likely  mechanism  for  this  type  of  disease  is 
immune related, occurring after the generation of free 
radicals, which are the end products of halothane hepatic 
metabolism (8). There is a lower risk of liver toxicity after 
consumption  of  newer  halogenated  anesthetics,  such 
as  enflurane,  isoflurane,  sevoflurane,  and  desflurane Hepat Mon. 2011;11(7):511-512
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(8), since they have lower metabolism rates in the liver. 
But,  compared  to  halothane,  these  agents  are  much 
more  expensive  (6-8).  In  other  words,  halothane  has 
been supplanted by its younger “brothers and sisters” 
at  a  higher  cost.  The  liver  related  complications  of 
these  agents,  although  they  have  decreased,  have  not 
disappeared,  while  the  effects  of  halothane  on  the 
pulmonary  and  cardiovascular  system  have  vanished. 
Can  halothane  gas  be  reintroduced  as  an  anesthetic 
and bronchodilative agent that does not have untoward 
effects on the liver?
2. The hypothesis
During  the  last  few  years,  nanoparticles  have  been 
increasingly a matter of interest in nearly all aspects of 
medicine, and much evidence has emerged regarding 
nanotechnology  in  medicine  (9,  10).  This  field  is  an 
evolving one that has seen many improvements, which 
are the result of its implications in medicine. One of the 
important issues that is considered in this field is the 
use of nanocarriers or nanomachines, which constitute 
a  nanoscale  delivery  system.  These  delivery  systems 
help  prevent  the  unwanted  exposure  of  tissues  to  a 
drug (11, 12). The issue is that halothane is an anesthetic 
agent with a relatively long history of clinical use as an 
anesthetic with beneficial cardiopulmonary effects and 
as a potent bronchodilator (3-6). Also, the drug is widely 
recognized and used in many parts of the world (6-8). If 
the halothane molecule could be altered in such a way 
that it could pass the lung and reach the brain and other 
organs,  except  for  the  liver,  the  new  molecule  could 
have all the useful effects of an inhalational anesthetic 
agent without causing major hepatic side effects. This 
could be the basis for producing halothane with such 
properties into which nanocarriers are inserted (13, 14). 
Since halothane is a well-known inhaled anesthetic that 
is used in many operating rooms, this nano-halothane 
would have a tremendous impact on the clinical practice 
of anesthesia (15).
3. Discussion of the hypothesis
There  are  many  opportunities  in  which  we  can  use 
current  and  emerging  nanotechnologies  to  produce 
entirely novel classes of therapeutics (16). There has been 
some progress in many fields, such as cancer therapy (17), 
and in producing new anesthetic agents, such as propofol 
(12),  which  are  all  accompanied  by  special  challenges. 
Of course, the problem with drugs like halothane is its 
elimination from hepatic uptake; usually, nanoproducts 
are  absorbed  in  the  liver  (18).  Yet,  it  seems  that  there 
are  many  methods  that  can  be  used  to  circumvent 
this  problem,  such  as  pegylation  of  drug  molecules. 
Producing  a  new  molecule  of  halothane  can  create 
prevent its untoward effects and while maintaining its 
benefits as an anesthetic agent.
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